Study of immunotherapy in antibody positive psychosis: feasibility and acceptability (SINAPPS1)
Abstract
The main finding of the SINAPPS1 study is that immunotherapy can be delivered rapidly and safely to people with acute psychosis within an acute hospital setting.
The treatments were tolerated and there were no cases of worsening of psychotic symptoms, even with the use of corticosteroids.
At 1 month after presentation, all patients had improved, although an uncontrolled study of this size cannot determine causality; that is the aim of the on-going randomised placebo-controlled SINAPPS2 trial, whose design was influenced by the current trial.
Citations
Belinda R Lennox, Giuliano Tomei,Sally-Anne Vincent, Ksenija Yeeles,Rebecca Pollard, Emma Palmer-Cooper,Peter Jones, Michael S Zandi, Alasdair Coles. Study of immunotherapy in antibody positive psychosis: feasibility and acceptability (SINAPPS1) J Neurol Neurosurg Psychiatry June 2018
Sponsorship: The study was funded by The Stanley Medical Research Institute (14T-004).
Page last reviewed: 12 June, 2025
Metadata
Author(s): Lennox, Belinda; Pollard, Rebecca; Tomei, Giuliano; Vincent, Sally-Anne; Yeeles, Ksenija
Collection: 123456789/31
Subject(s): Encephalitis, Immunotherapy, Psychosis
Format(s): Article
Date issued: 2018-06-11
ISSN: 1468-330X
ID: 86